TB-500
Research OnlyAlso known as: Thymosin Beta-4 Fragment, TB4-FRAG, TMSB4X
A synthetic fragment of thymosin beta-4 marketed for tissue repair. While the parent compound has Phase 3 clinical research (RGN-259), TB-500 specifically has no published human data.
Research Statistics
Synthetic fragment of thymosin beta-4 (Ac-SDKP). Similar evidence profile to BPC-157: primarily preclinical with some equine/veterinary use. Actin sequestration and angiogenesis mechanisms are proposed and supported by in vitro data. Limited human trial data.
Research Dossier
Overview
What is TB-500 and what does the research say?
Mechanism of Action
The proposed mechanisms are largely extrapolated from thymosin beta-4 research, not TB-500 specifically.
How It Works (Simplified)
TB-500 is a fragment of thymosin beta-4 that acts as a “repair signal” through several pathways:
Binds G-actin to regulate cytoskeletal dynamics, making cells more flexible and able to move to injury sites.
Promotes keratinocyte and fibroblast migration to wound sites, increasing re-epithelialization by 42-61% in animal models.
Activates ILK-Akt pathway promoting cell survival, particularly cardioprotective in myocardial injury models.
Suppresses NF-kB and modulates microRNA-146a pathway, reducing excessive inflammatory responses and fibrosis.
Scientific Pathways
Actin-Binding Pathway (Cell Migration)
TB-500 (LKKTETQ motif) → G-actin binding → Prevents polymerization
↓
Cytoskeletal reorganization
↓
Enhanced cell migrationILK-Akt Pathway (Cell Survival)
TB-500 → ILK activation → Akt phosphorylation → Bcl-2 → Cell survivalKey Research: Bock-Marquette et al. (Nature, 2004) demonstrated ILK-Akt activation in cardiac tissue. PMID:15565145
Important Limitations
- All research is on parent compound (thymosin beta-4), not TB-500 specifically
- TB-500 is a fragment that may not replicate full Tb4 effects
- No human clinical trials have studied TB-500 directly
- RGN-259 (full Tb4) Phase 3 trial for corneal healing failed primary endpoint in 2025
- Translation from preclinical to human outcomes is unconfirmed
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on parent compound (Thymosin Beta-4) research: Initial effects on cell migration and cytoskeletal remodeling may begin. Equine studies showed early anti-inflammatory response. No TB-500 specific human data exists.
Animal studies with Thymosin Beta-4 show wound healing improvements by 2-4 weeks. Corneal healing studies demonstrated accelerated epithelialization within this timeframe.
Preclinical cardiac models showed improved function by 4-8 weeks post-MI. Neurological studies indicated ongoing neuroregeneration and oligodendrogenesis in this period.
Long-term effects in animal models suggest sustained tissue repair. Phase 3 RGN-259 ophthalmology trials showed healing at 28 days for corneal conditions. Human timeline for TB-500 specifically is unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate TB-500 product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining TB-500 with other peptides. Based on published research and mechanistic considerations.
BPC-157
SynergisticFrequently combined for tissue repair research. TB-500's actin-sequestering and cell migration effects may complement BPC-157's cytoprotective and angiogenic pathways. No clinical combination studies exist.
GHK-Cu
CompatibleBoth promote wound healing through different mechanisms. TB-500 modulates actin dynamics while GHK-Cu activates copper-dependent signaling. Theoretically complementary.
Thymosin-Alpha-1
CompatibleDifferent thymosin family members with distinct functions. Thymosin Alpha-1 focuses on immune modulation while TB-500 (Thymosin Beta-4 fragment) targets tissue repair.
Ipamorelin
CompatibleNon-overlapping mechanisms. GH secretagogues like ipamorelin may theoretically support tissue repair processes. No direct interaction data.
CJC-1295
CompatibleGHRH analog with different target system. May complement tissue repair through GH/IGF-1 pathway. No known contraindications.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare TB-500
TB-500 Calculators
Related Peptides
Cartalax
AED peptide, Ala-Glu-Asp, cartilage bioregulator
A synthetic tripeptide (Ala-Glu-Asp) from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair and chondrocyte function. All research originates from Russian institutes with no independent Western validation or controlled human clinical trials.
GHK-Cu
Copper Peptide GHK, Glycyl-L-Histidyl-L-Lysine:Copper
A naturally occurring copper-binding tripeptide with wound healing and skin regeneration properties. Extensively studied globally with moderate-to-high evidence for cosmetic applications.
GHK
Glycyl-Histidyl-Lysine, GHK tripeptide, Liver cell growth factor
A naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
Sigumir
Cartilage cytamin, Joint peptides, A-6 cartilage peptides
A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for joint and cartilage support. Contains peptide complexes rather than defined sequences. No Western clinical validation.